Prab: CSV import

2025-02-13T03:54:39Z

CSV import

← Older revision		Revision as of 03:54, 13 February 2025
Line 1:		Line 1:
	~~{{Short description\|An article about the drug Adavosertib}}~~		== Adavosertib ==
	~~{{Drugbox~~
	~~\| verifiedfields~~ = ~~changed~~
	~~\| verifiedrevid~~ = ~~477002123~~
	~~\| IUPAC_name~~ = ~~N-((3-(3-(4-(morpholin-4-yl)phenyl)ureido)phenyl)carbamoyl)benzamide~~
	~~\| image~~ = ~~Adavosertib.svg~~
	}}

	~~'''Adavosertib''' is a small molecule inhibitor of the~~ [[~~WEE1 kinase]], a protein that plays a critical role in the regulation of the [[cell cycle]]~~. ~~It is being investigated for its potential use in the treatment~~ of ~~various types of [[cancer~~]].		[[File:Adavosertib.svg\|thumb\|right\|Chemical structure of Adavosertib]]

	~~==Mechanism of Action==~~		'''Adavosertib''' is a small molecule inhibitor of the [[WEE1]] kinase, which plays a crucial role in the regulation of the [[cell cycle]]. It is being investigated for its potential use in the treatment of various types of [[cancer]].
	Adavosertib ~~functions by inhibiting the activity~~ of the [[WEE1 ~~kinase~~]], which ~~is involved~~ in the ~~[[G2/M checkpoint]]~~ of the ~~cell cycle. This checkpoint is crucial for ensuring that cells do not enter [[mitosis]] with damaged [[DNA]]. By inhibiting WEE1, adavosertib disrupts this checkpoint, leading to~~ [[cell cycle ~~arrest~~]] ~~and potentially enhancing~~ the ~~effects~~ of [[~~DNA-damaging agents]] such as [[chemotherapy]] and [[radiation therapy~~]].

	==~~Clinical Development~~==		=== Mechanism of Action ===
	Adavosertib is currently undergoing clinical trials to evaluate its efficacy and safety in combination with other cancer therapies. It has shown promise in preclinical studies and early-phase clinical trials, particularly in cancers with [[p53 mutations]], where the G1 checkpoint is compromised, making the G2/M checkpoint more critical.

	~~==Potential Applications==~~		Adavosertib functions by inhibiting the activity of the WEE1 kinase. WEE1 is a key regulator of the [[G2/M checkpoint]] in the cell cycle. By inhibiting WEE1, adavosertib prevents the phosphorylation of [[cyclin-dependent kinase 1]] (CDK1), leading to the premature entry of cells into [[mitosis]]. This can result in [[mitotic catastrophe]] and [[apoptosis]] in cancer cells, particularly those with defective [[p53]] pathways.
	~~The primary focus~~ of ~~adavosertib research~~ is in the ~~treatment~~ of [[~~ovarian cancer~~]], [[~~breast cancer~~]], and ~~other solid tumors. Its ability to sensitize~~ cancer cells to [[~~DNA damage~~]] ~~makes it a promising candidate for combination therapy with existing treatments~~.

	==~~Side Effects~~==		=== Clinical Development ===
	~~As with many~~ cancer ~~therapies~~, adavosertib ~~can cause~~ a ~~range of side effects~~. ~~Commonly reported~~ side effects include [[nausea]], [[fatigue]], and [[hematological toxicity]]. ~~Ongoing clinical trials continue to monitor~~ and ~~evaluate the safety profile of adavosertib~~.
			Adavosertib is currently undergoing clinical trials for its efficacy in treating various cancers, including [[ovarian cancer]], [[breast cancer]], and [[colorectal cancer]]. It is often studied in combination with other chemotherapeutic agents to enhance its anticancer effects.

			=== Pharmacokinetics ===

			The pharmacokinetic profile of adavosertib includes its absorption, distribution, metabolism, and excretion. It is administered orally and has been shown to have a favorable bioavailability. The drug is metabolized primarily in the liver and excreted through the kidneys.

			=== Side Effects ===

			Common side effects of adavosertib include [[nausea]], [[diarrhea]], [[fatigue]], and [[hematological toxicity]]. These side effects are generally manageable with supportive care and dose adjustments.

			== Related Pages ==

	~~==Related pages==~~
	* [[WEE1 kinase]]		* [[WEE1 kinase]]
	* [[Cell cycle]]		* [[Cell cycle]]
	* [[Cancer treatment]]		* [[Cancer treatment]]
	* [[~~Chemotherapy~~]]		* [[Apoptosis]]

	~~==Gallery==~~
	~~<gallery>~~
	~~File:Adavosertib.svg\|Chemical structure of Adavosertib~~
	~~</gallery>~~

	[[Category:~~Antineoplastic~~ drugs]]		[[Category:Anticancer drugs]]
	[[Category:~~Experimental cancer drugs~~]]		[[Category:Cell cycle inhibitors]]

Prab: CSV import

2025-02-11T21:54:06Z

CSV import

New page

{{Short description|An article about the drug Adavosertib}}
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = N-((3-(3-(4-(morpholin-4-yl)phenyl)ureido)phenyl)carbamoyl)benzamide
| image = Adavosertib.svg
}}

'''Adavosertib''' is a small molecule inhibitor of the [[WEE1 kinase]], a protein that plays a critical role in the regulation of the [[cell cycle]]. It is being investigated for its potential use in the treatment of various types of [[cancer]].

==Mechanism of Action==
Adavosertib functions by inhibiting the activity of the [[WEE1 kinase]], which is involved in the [[G2/M checkpoint]] of the cell cycle. This checkpoint is crucial for ensuring that cells do not enter [[mitosis]] with damaged [[DNA]]. By inhibiting WEE1, adavosertib disrupts this checkpoint, leading to [[cell cycle arrest]] and potentially enhancing the effects of [[DNA-damaging agents]] such as [[chemotherapy]] and [[radiation therapy]].

==Clinical Development==
Adavosertib is currently undergoing clinical trials to evaluate its efficacy and safety in combination with other cancer therapies. It has shown promise in preclinical studies and early-phase clinical trials, particularly in cancers with [[p53 mutations]], where the G1 checkpoint is compromised, making the G2/M checkpoint more critical.

==Potential Applications==
The primary focus of adavosertib research is in the treatment of [[ovarian cancer]], [[breast cancer]], and other solid tumors. Its ability to sensitize cancer cells to [[DNA damage]] makes it a promising candidate for combination therapy with existing treatments.

==Side Effects==
As with many cancer therapies, adavosertib can cause a range of side effects. Commonly reported side effects include [[nausea]], [[fatigue]], and [[hematological toxicity]]. Ongoing clinical trials continue to monitor and evaluate the safety profile of adavosertib.

==Related pages==
* [[WEE1 kinase]]
* [[Cell cycle]]
* [[Cancer treatment]]
* [[Chemotherapy]]

==Gallery==
<gallery>
File:Adavosertib.svg|Chemical structure of Adavosertib
</gallery>

[[Category:Antineoplastic drugs]]
[[Category:Experimental cancer drugs]]

Adavosertib - Revision history

Prab: CSV import

Prab: CSV import